[ad_1]
Scientists from Brittany, headed by two Greek found that a percentage of people, especially young people, who have never been infected with the coronavirus SARS-CoV-2, therefore, they did not get sick from the disease COVID-19, have a relative natural immunity thanks to the pre-existing antibodies in organism that can neutralize, at least in part, the new virus.
The researchers, led by him George Cassioti from high school Francis Creek London and Helena Nastouli University College London (UCL), published in the journal Science, found that of the 302 adults tested, 16 (5.3%) had IgG antibodies against SARS-CoV-2, likely created during infections in the past by the much more seasonal coronaviruses. common cold.
Also between 48 children Y teenagers from one to 16 years studied, 21 (44%) detected Similary antibodies.
These Preexisting antibodies react in a specific region (the so-called S2 subunit) of the prominent coronavirus penetrate and infect human cells.
The module S2 larger sample structural similarities in all coronaviruses, relative to the S1 subunit of the same viral protein.
Although previous studies show that this “cross” immunity from other related viruses does not guarantee that someone will not be infected with the new coronavirus, the presence of pre-existing antibodies can reduce the transmissibility of the virus and mitigate symptoms in case of infection.
Experiments with cell phone crops In the laboratory, it was shown that the blood plasma of adults and children with antibodies without being infected with Covid-19 could fight the new coronavirus. That was not the case with blood plasma of individuals without such pre-existing antibodies.
According to the researchers, these findings suggest that targeting the specific S2 region of the virus’s new protein spike could be the basis for a universal vaccine, which will “work” against many coronaviruses at the same time.
In comparison, those who have been infected SARS-CoV-2, develop along the way older numbers all types of antibodies (IgA, IgG and IgM), which target the S1 and S2 subunits of the coronavirus protein.
